David W Berman

US Patent:

20080057071, Mar 6, 2008

Filed:

Oct 20, 2004

Appl. No.:

10/576149

Inventors:

David N. Watkins - Baltimore MD, US
David M. Berman - Towson MD, US
Stephen B. Baylin - Baltimore MD, US
Philip A. Beachy - Towson MD, US

International Classification:

A61K 39/395
A61K 31/42
A61P 35/00
C12N 5/08
C12Q 1/68
G01N 33/53

US Classification:

4241581, 435375, 435 6, 435 78, 514 12, 514278

Abstract:

Elevated Hedgehog (Hh) pathway activity, including ligand stimulated Hh pathway activity, was detected in small-cell lung cancer (SCLQ cells, and determined to be associated with growth and proliferation of the cancer cells. Accordingly, methods are provided for treating SCLC associated with elevated Hh pathway activity by reducing or inhibiting the Hh pathway activity. Also provided are methods of determining the responsiveness of SCLC to treatment with a Hh pathway antagonist.

US Patent:

20080095761, Apr 24, 2008

Filed:

Oct 1, 2004

Appl. No.:

10/572430

Inventors:

Philip A. Beachy - Towson MD, US
David M. Berman - Towson MD, US
Sunil S. Karhadkar - Towson MD, US

Assignee:

THE JOHNS HOPKINS UNIVERSITY - Baltimore MD

International Classification:

A61K 39/395
A61K 31/4355
A61K 31/7105
C12Q 1/48
C12Q 1/68
C12Q 1/02
A61K 38/16

US Classification:

4241301, 435 15, 435 29, 435 6, 435 71, 514 12, 514278, 514 44

Abstract:

Elevated Hedgehog (Hh) pathway activity, including ligand stimulated Hh pathway activity, was detected in prostate tumors, and determined to be associated with growth and proliferation of the cancer cells. Accordingly, methods are provided for treating a prostate cancer associated with elevated Hh pathway activity by reducing or inhibiting the Hh pathway activity. Also provided are methods of determining the responsiveness of a prostate tumor to treatment with an Hh pathway antagonist.

US Patent:

20080118493, May 22, 2008

Filed:

Jul 15, 2004

Appl. No.:

10/564580

Inventors:

Philip A. Beachy - Towson MD, US
David Monty Berman - Towson MD, US
Sunil S. Karhadkar - Towson MD, US
Anirban Maitra - Kensington MD, US

International Classification:

A61K 31/395
C12N 5/04
A61K 38/00
A61K 31/70
C12Q 1/20
C12Q 1/68

US Classification:

4241301, 435375, 514 2, 514 44, 435 29, 435 6

Abstract:

Elevated Hedgehog (Hh) pathway activity, including ligand stimulated Hh pathway activity, was detected in digestive tract cancers, including esophagus, stomach, biliary tract, and pancreatic cancer, and determined to be associated with growth and proliferation of the cancer cells. Accordingly, methods are provided for treating a digestive tract cancer associated with elevated Hh pathway activity by reducing or inhibiting the Hh pathway activity. Also provided are methods of determining the responsiveness of a digestive tract tumor to treatment with an Hh pathway antagonist.

US Patent:

20090047212, Feb 19, 2009

Filed:

Mar 24, 2008

Appl. No.:

12/079078

Inventors:

David M. Berman - Towson MD, US
William Matsui - Baltimore MD, US
Xiaobing He - Baltimore MD, US

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

A61K 51/08
A61P 35/00
A61K 39/395
A61B 5/055
A61K 49/00
A61K 51/10

US Classification:

424 149, 4241301, 424 93, 424 96, 424 111, 4241781, 4241831

Abstract:

The present invention provides a method of treating cancer in a patient (e.g., a human patient) in need thereof, the method comprising administering a therapeutically effective regimen, the regimen comprising administering to a patient in need thereof a compound that targets 67 laminin receptor (67LR). In a particular embodiment, the compound that targets 67LR is an antibody or antibody fragment. In particular, the present invention provides a method of treating cancer comprising administering to a patient in need thereof an antibody that binds to 67LR. The present invention also provides a method of treating cancer comprising administering to a patient in need thereof an antibody conjugate, wherein the antibody conjugate comprises an antibody that binds to 67LR linked to a therapeutic agent, a protein toxin, a cytotoxic agent or other moiety. The present invention provides pharmaceutical compositions for the treatment of cancer comprising an antibody that binds to 67LR in an amount effective to reduce cancer stem cells and/or cancer cells in a patient. The invention also provides for means to detect and monitor cancer stem cells based on their expression of 67LR.

US Patent:

20110020221, Jan 27, 2011

Filed:

Apr 9, 2010

Appl. No.:

12/757649

Inventors:

David M. Berman - Towson MD, US
Xiaobing He - Ann Arbor MI, US
William Matsui - Baltimore MD, US

Assignee:

THE JOHNS HOPKINS UNIVERSITY - Baltimore MD

International Classification:

A61K 39/395
A61P 35/00
A61K 51/00
A61P 35/02

US Classification:

424 149, 4241301, 4241781, 4241381, 4241581

Abstract:

Described herein are therapeutic targets expressed in cancer stem cells and methods for treating and diagnosing cancer by targeting such cells with antibodies, compounds, nucleic acid, or other therapeutic agent. In one embodiment described herein, therapeutic agents for the treatment of cancer are provided based on the identification of cancer stem cell targets. The present invention also includes therapeutic targets for cancer therapy and cancer stem cell-targeted therapy. The invention includes the treatment of cancer by the administration of compounds or agents that target cancer stem cells.

Author:

David Berman

ISBN #:

0198264674

Author:

David Berman

ISBN #:

0198267460

Author:

David Berman

ISBN #:

0460875051

Author:

David Berman

ISBN #:

0709932715

Author:

David Berman

ISBN #:

0824024443

Author:

David Berman

ISBN #:

0826485901

Author:

David Berman

ISBN #:

0765610868

Author:

David Berman

ISBN #:

0863271766